Valcadia Healthcare Partners Advises CURC in its Acquisition by The START Center for Cancer Research

Audio By Carbonatix

DENVER--(BUSINESS WIRE)--Dec 15, 2025--

Valcadia Healthcare Partners LLC (“Valcadia”) a leading healthcare investment banking and M&A advisory firm, announced today that it has advised Carolina Urologic Cancer Center (“CURC”), the premier urologic clinical research site specializing in genitourinary oncology, in its acquisition by The START Center for Cancer Research, a global leader in early-phase oncology clinical trials. The transaction closed in April 2025 and represents Valcadia’s fourth completed outsourced pharma services transaction, a milestone which reflects the firm’s leadership in advising health sciences entrepreneurs and business owners.

Founded in 1998 by Neal Shore, MD, FACS, CURC has conducted nearly 500 clinical trials, making it the top urologic oncology site worldwide by both volume and quality. With deep expertise in early phase as well as late phase trials, CURC brings unparalleled leadership and scientific insight to START's global research portfolio. With the integration of CURC’s specialized trial capabilities and expertise and to further strengthen its leadership in GU oncology research, START has established a dedicated Center of Excellence (COE) focused on delivering a comprehensive trial solution for urological cancers.

“Joining START’s global site network marks an exciting new chapter for CURC,” said Dr. Neal Shore, Founder and Medical Director of CURC. “START is the leader in early phase oncology trials, and we share a mission to bring the hope of clinical trials to patients worldwide. I am honored to lead START’s GU Oncology growth as well as their commitment to radiopharmaceutical trial expansion.”

“Valcadia Healthcare Partners was essential in helping CURC identify the right strategic partner,” added Dr. Shore. “I strongly recommend Valcadia as they displayed unwavering professionalism, insight and diligence in guiding us through this successful transaction."

“We are honored to have advised CURC through this pivotal partnership,” said Ethan Goodson, Founder and Managing Partner at Valcadia Healthcare Partners. “Dr. Shore and the entire CURC team have built a leading community-based urologic oncology research practice grounded in clinical excellence and strengthened by a mission-driven culture that permeates the entire organization. We are proud to have supported them in securing a partner that will preserve and build upon that identity, and we look forward to following their continued growth and success.”

Bass, Berry & Sims PLC provided legal counsel to CURC in connection with the transaction, and ReedSmith LLP provided legal counsel to START.

About Carolina Urologic Research Center

Carolina Urologic Research Center (CURC), now known as START Carolinas, has been recognized both nationally and internationally as one of the most progressive and respected clinical research sites in the United States. CURC employs a highly skilled group of healthcare professionals, including 6 board-certified urologists and 22 full-time research staff. Over the past 25 years, CURC has participated in approximately 500 national and international clinical research trials for patients with various urologic conditions. Learn more at https:// https://startresearch.com/start-carolinas

For more information please visit www.valcadiahealthcarepartners.com.

Valcadia Healthcare Partners LLC, 66 S. Logan Street, Denver, CO 80209

View source version on businesswire.com:https://www.businesswire.com/news/home/20251215297461/en/

[email protected]

KEYWORD: COLORADO UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BUSINESS HEALTH PROFESSIONAL SERVICES CLINICAL TRIALS ONCOLOGY

SOURCE: Valcadia Healthcare Partners LLC

Copyright Business Wire 2025.

PUB: 12/15/2025 01:16 PM/DISC: 12/15/2025 01:17 PM

http://www.businesswire.com/news/home/20251215297461/en